{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-110971","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2026-09-25T20:10:39+00:00","discovered_at":"2026-09-25T20:11:41.278854+00:00","generated_at":"2026-10-12T13:22:36.320407+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NextCure seeks Delaware court validation of 2025 reverse split tied to Avere merger","bullets":["NextCure filed a Section 205 petition on Sept. 14, 2026, in Delaware Court of Chancery seeking validation of its 1:12 reverse split filed July 10, 2025.","The 2025 reverse split drew 18,166,577 votes for, 2,028,946 against and 6,613 abstentions; 64.76% of outstanding shares backed it, short of the 66 2/3% supermajority.","The Delaware Court of Chancery scheduled a hearing for Nov. 6, 2026, at 3:00 p.m. ET; stockholder opposition submissions are due by Oct. 27, 2026, to the Register in Chancery.","NextCure plans a 2026 reverse split under the supermajority standard tied to its Avere Therapeutics combination; failure could delay or block that merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-110971","json":"https://secwatch.observer/filing/0001104659-26-110971.json","markdown":"https://secwatch.observer/filing/0001104659-26-110971.md","text":"https://secwatch.observer/filing/0001104659-26-110971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926110971/0001104659-26-110971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926110971/nxtc-20260921x8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:22:36.320407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}